Contact
searchSearch
HMP Global
Login

Melanoma

Melanoma
Specialty Channel
Georgina Long, MD, PhD
Videos
Neoadjuvant Nivolumab Plus Relatlimab Produces Deep Responses in High-Risk Melanoma
06/19/2026
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses results from the phase 2 NEO-RENI-2 trial showing that neoadjuvant nivolumab plus relatlimab achieved a 60% pathologic complete response rate and 65% major pathologic response rate in patients with resectable...
Georgina Long, MD, PhD, discusses results from the phase 2 NEO-RENI-2 trial showing that neoadjuvant nivolumab plus relatlimab achieved a 60% pathologic complete response rate and 65% major pathologic response rate in patients with resectable...
Georgina Long, MD, PhD,...
06/19/2026
Oncology
Katharina Kaehler, MD
Videos
Novel Neoadjuvant Approach Expands Treatment Options for Patients With Melanoma
06/18/2026
Katharina Kaehler, MD
Katharina Kaehler, MD, discusses updated results from the phase 3 PIVOTAL trial showing that neoadjuvant intralesional immunotherapy significantly improved relapse-free, distant metastasis-free, and event-free survival compared with upfront...
Katharina Kaehler, MD, discusses updated results from the phase 3 PIVOTAL trial showing that neoadjuvant intralesional immunotherapy significantly improved relapse-free, distant metastasis-free, and event-free survival compared with upfront...
Katharina Kaehler, MD, discusses...
06/18/2026
Oncology
Marlana Orloff, MD
Videos
Darovasertib Plus Crizotinib Combination Demonstrates Meaningful Clinical Benefit in Metastatic Uveal Melanoma
06/15/2026
Marlana Orloff, MD
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses...
06/15/2026
Oncology
Janice Mehnert, MD
Videos
Adjuvant Pembrolizumab Reduces Distant Recurrence Risk in Merkel Cell Carcinoma
06/12/2026
Janice Mehnert, MD
Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...
Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...
Janice Mehnert, MD, discusses...
06/12/2026
Oncology
News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
Jessica Hassel, MD
Videos
Immune Modulatory Vaccine Plus Pembrolizumab for First-Line Treatment of Patients With Advanced Melanoma
10/30/2025
Jessica Hassel, MD
Jessica Hassel, MD, shares results from a phase 3 trial evaluating the IO102-IO103 cancer vaccine in combination with pembrolizumab in the first-line setting for patients with advanced melanoma in the first line.
Jessica Hassel, MD, shares results from a phase 3 trial evaluating the IO102-IO103 cancer vaccine in combination with pembrolizumab in the first-line setting for patients with advanced melanoma in the first line.
Jessica Hassel, MD, shares...
10/30/2025
Oncology
News
Nivolumab Plus Relatlimab Demonstrates Long-Term Efficacy, Safety Among Newly Diagnosed Patients With Advanced Unresectable Melanoma
08/19/2025
Stephanie Holland
According to results from the phase 2/3 RELATIVITY-047 trial, nivolumab plus relatlimab demonstrated durable long-term efficacy and safety among newly diagnosed patients with advanced unresectable melanoma.
According to results from the phase 2/3 RELATIVITY-047 trial, nivolumab plus relatlimab demonstrated durable long-term efficacy and safety among newly diagnosed patients with advanced unresectable melanoma.
According to results from the...
08/19/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology

News

News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
News
Nivolumab Plus Relatlimab Demonstrates Long-Term Efficacy, Safety Among Newly Diagnosed Patients With Advanced Unresectable Melanoma
08/19/2025
Stephanie Holland
According to results from the phase 2/3 RELATIVITY-047 trial, nivolumab plus relatlimab demonstrated durable long-term efficacy and safety among newly diagnosed patients with advanced unresectable melanoma.
According to results from the phase 2/3 RELATIVITY-047 trial, nivolumab plus relatlimab demonstrated durable long-term efficacy and safety among newly diagnosed patients with advanced unresectable melanoma.
According to results from the...
08/19/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology
Conference Coverage
Neoadjuvant Pembrolizumab for Treatment-Naive Patients With Stage IIB/IIC Melanoma
06/17/2025
Stephanie Holland
According to results from a multicenter, phase 2 trial, neoadjuvant pembrolizumab demonstrated both efficacy and safety among patients with stage IIB/IIC melanoma without risking increased sentinel lymph node metastasis.
According to results from a multicenter, phase 2 trial, neoadjuvant pembrolizumab demonstrated both efficacy and safety among patients with stage IIB/IIC melanoma without risking increased sentinel lymph node metastasis.
According to results from a...
06/17/2025
Oncology
News
Adjuvant Pembrolizumab Continues to Prolong Survival Outcomes Among Patients With Stage IIB/IIC Melanoma
05/12/2025
Stephanie Holland
According to long-term follow-up results from the KEYNOTE-716 trial, adjuvant pembrolizumab continued to prolong survival outcomes among patients with stage IIB/IIC melanoma.
According to long-term follow-up results from the KEYNOTE-716 trial, adjuvant pembrolizumab continued to prolong survival outcomes among patients with stage IIB/IIC melanoma.
According to long-term follow-up...
05/12/2025
Oncology
News
Addition of Short-Term Targeted Therapy Provides Long-Term Survival Benefit for Patients With Advanced Melanoma
05/06/2025
Stephanie Holland
According to updated survival results from the IMPemBra trial, the addition of short-term targeted therapy to anti-PD1 inhibition demonstrated long-term survival benefit among treatment-naive patients with BRAFV600E/K-mutated advanced...
According to updated survival results from the IMPemBra trial, the addition of short-term targeted therapy to anti-PD1 inhibition demonstrated long-term survival benefit among treatment-naive patients with BRAFV600E/K-mutated advanced...
According to updated survival...
05/06/2025
Oncology
News
Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma
04/11/2025
Stephanie Holland
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
According to results from the...
04/11/2025
Oncology

Interactive Features

Quiz
Quiz: Does Pembrolizumab Plus Ipilimumab Lead to Antitumor Activity in Melanoma?
08/26/2021
True or false: In a recent phase 2 trial, pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity and tolerability for patients with melanoma after anti-PD-1 immunotherapy failure.
True or false: In a recent phase 2 trial, pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity and tolerability for patients with melanoma after anti-PD-1 immunotherapy failure.
True or false: In a recent phase...
08/26/2021
Oncology
Test Your Knowledge
Quiz: Nomograms Developed to Predict Recurrences in Patients with T1 Melanomas
03/26/2021
True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
True or False: The nomograms in...
03/26/2021
Oncology
Test Your Knowledge
Quiz: Combining Low-Dose Ipilimumab With Pembrolizumab in Melanoma
06/22/2020
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
True or False: In a phase 2...
06/22/2020
Oncology
Test Your Knowledge
Quiz: What Factors Increase Risk for AEs in Patients With Melanoma?
05/25/2020
True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.
True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.
True or False: The risk for...
05/25/2020
Oncology
Test Your Knowledge
Quiz: Can Adverse Events Indicate Pembrolizumab Activity in Stage III Melanoma?
03/06/2020
True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.
True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.
True or False: Immune-related...
03/06/2020
Oncology
Test Your Knowledge
Quiz: Mohs Micrographic Surgery vs Traditional Excision for Melanoma
02/13/2020
True or False: Compared with excision, Mohs micrographic surgery moderately improves overall survival in patients with early-stage invasive melanoma.
True or False: Compared with excision, Mohs micrographic surgery moderately improves overall survival in patients with early-stage invasive melanoma.
True or False: Compared with...
02/13/2020
Oncology

Recent News

News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
News
Nivolumab Plus Relatlimab Demonstrates Long-Term Efficacy, Safety Among Newly Diagnosed Patients With Advanced Unresectable Melanoma
08/19/2025
Stephanie Holland
According to results from the phase 2/3 RELATIVITY-047 trial, nivolumab plus relatlimab demonstrated durable long-term efficacy and safety among newly diagnosed patients with advanced unresectable melanoma.
According to results from the phase 2/3 RELATIVITY-047 trial, nivolumab plus relatlimab demonstrated durable long-term efficacy and safety among newly diagnosed patients with advanced unresectable melanoma.
According to results from the...
08/19/2025
Oncology
Conference Coverage
Neoadjuvant Pembrolizumab for Treatment-Naive Patients With Stage IIB/IIC Melanoma
06/17/2025
Stephanie Holland
According to results from a multicenter, phase 2 trial, neoadjuvant pembrolizumab demonstrated both efficacy and safety among patients with stage IIB/IIC melanoma without risking increased sentinel lymph node metastasis.
According to results from a multicenter, phase 2 trial, neoadjuvant pembrolizumab demonstrated both efficacy and safety among patients with stage IIB/IIC melanoma without risking increased sentinel lymph node metastasis.
According to results from a...
06/17/2025
Oncology
News
Adjuvant Pembrolizumab Continues to Prolong Survival Outcomes Among Patients With Stage IIB/IIC Melanoma
05/12/2025
Stephanie Holland
According to long-term follow-up results from the KEYNOTE-716 trial, adjuvant pembrolizumab continued to prolong survival outcomes among patients with stage IIB/IIC melanoma.
According to long-term follow-up results from the KEYNOTE-716 trial, adjuvant pembrolizumab continued to prolong survival outcomes among patients with stage IIB/IIC melanoma.
According to long-term follow-up...
05/12/2025
Oncology
News
Addition of Short-Term Targeted Therapy Provides Long-Term Survival Benefit for Patients With Advanced Melanoma
05/06/2025
Stephanie Holland
According to updated survival results from the IMPemBra trial, the addition of short-term targeted therapy to anti-PD1 inhibition demonstrated long-term survival benefit among treatment-naive patients with BRAFV600E/K-mutated advanced...
According to updated survival results from the IMPemBra trial, the addition of short-term targeted therapy to anti-PD1 inhibition demonstrated long-term survival benefit among treatment-naive patients with BRAFV600E/K-mutated advanced...
According to updated survival...
05/06/2025
Oncology
News
Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma
04/11/2025
Stephanie Holland
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
According to results from the...
04/11/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Ipilimumab Plus Nivolumab Sustains Efficacy Among Patients With Asymptomatic Melanoma Brain Metastases
03/10/2025
Stephanie Holland
According to long-term follow-up results from a phase 2 study, ipilimumab plus nivolumab demonstrated long-term efficacy among immunotherapy-naive patients with asymptomatic melanoma brain metastases.
According to long-term follow-up results from a phase 2 study, ipilimumab plus nivolumab demonstrated long-term efficacy among immunotherapy-naive patients with asymptomatic melanoma brain metastases.
According to long-term follow-up...
03/10/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
Immunotherapy Plus Hypofractionated Radiotherapy Fails to Improve Survival for Treatment-Naive Melanoma
01/29/2025
Stephanie Holland
According to results from a phase 2 trial, immunotherapy plus hypofractionated radiotherapy did not improve survival among patients with treatment-naive metastatic melanoma.
According to results from a phase 2 trial, immunotherapy plus hypofractionated radiotherapy did not improve survival among patients with treatment-naive metastatic melanoma.
According to results from a...
01/29/2025
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use